Eurobench.com

RW1963 28 februari 2020 15:13

0

quote:
rationeel schreef op 28 februari 2020 14:21:
[...]

Hier is de aanleiding voor het pb:

today announces that the Company will... present... first preclinical results on OX401,... its... next-generation... PARP inhibitor (PARPi),... during a poster session at the... ESMO-TAT1 Congress 2020 ...dedicated to the research on targeted cancer therapies, to be held in... Paris, France,... on... March 2-4, 2020...

Daar ontmoeten ze elkaar, en kunnen misschien zaken doen;)

Bedankt, maar zoals ik al zei vind ik het knap lastig al die Engelse (technische) teksten te lezen.

Ach ja, als het paar positief is.

Welke bedrijven noemde jij in het Corona-verhaal? Niet dat ik ze kopen wil (heb mijn neus al een paar keer flink gestoten), maar wil wel meekijken.

RW1963 9 maart 2020 10:16

0

20% er af vandaag :-(
Met dit aandeel komt het voor mij nooit meer goed.

rationeel 27 maart 2020 21:47

0

Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces the postponement of the publication of its 2019 full-year results until April 17, 2020, after the close of trading.

Indeed, due to the constraints imposed by the current context, the meeting of the Board of Directors to close the accounts, which was scheduled for March 31, 2020, has been postponed to April 17, 2020. As a result, the Combined General Meeting, initially scheduled to be held on May 13, 2020, is postponed to May 29, 2020.

RW1963 9 april 2020 09:44

0

Het wordt tijd dat dit aandeel ook eens een sprong voorwaarts gaat maken zoals sommige aandelen dat ook doen in deze Corona-tijd ;-)

rationeel 15 april 2020 15:08

0

Onxeo reçoit 6,6 M$ en contrepartie de la concession de droits exclusifs additionnels sur belinostat à Acrotech Biopharma.

www.boursier.com/actions/actualites/n...

rationeel 15 april 2020 15:14

0

Boven 0,5306 blijven dan is het aandeel uit het dalende kanaal.

rationeel 15 april 2020 15:53

0

Onxeo : to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

> This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology
> $6.6m received from Acrotech extends Onxeo’s cash runway into Q2 2021 and supports Company’s DDR-related programs

rationeel 15 april 2020 17:00

0

INVITATION

To mark the publication of its 2019 Full Year Results, the management team of Onxeo is pleased to invite you to a conference call on:

Friday, April 17, 2020 at 6:15 pm CEST

followed by a Q&A session.

The call will be accessible via the below conference call details:

France: +33 1 72 72 74 03
United States: +1 646 7224 916
United Kingdom: +44 20 71943 759
Denmark: +458 23 33 187

PIN code: 47169541#

You can also follow the slideshow presentation on the web:

www.anywhereconference.com?Conference...

RW1963 15 april 2020 17:45

0

quote:
rationeel schreef op 15 april 2020 15:14:
Boven 0,5306 blijven dan is het aandeel uit het dalende kanaal.

Net aan gelukt ;-)

Kom nu maar op. Lang genoeg gewacht.

rationeel 17 april 2020 14:32

0

Bijna ob.

Prettig wanneer het aandeel vervolgens bij het retracen boven de 51,09...46,86 blijft.

RW1963 24 april 2020 19:26

0

quote:
rationeel schreef op 17 april 2020 14:32:
Bijna ob.

Prettig wanneer het aandeel vervolgens bij het retracen boven de 51,09...46,86 blijft.

Ver eronder !

rationeel 27 april 2020 15:42

0

50% retracement op de dag...0,4575.

0,514 bovenkant neerwaartse kanaal. Zit hij nu weer tegenaan:(

Indien het aandeel boven de 0,4575 de nieuwe bodem zet, dan kan deze weerstand overwonnen worden.

Houd goede moed:)

rationeel 19 mei 2020 19:16

0

Paris (France), May 19, 2020 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the presentation of preclinical data supporting the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth. These promising results will be presented in an e-posters session during the American Association for Cancer Research (AACR) annual meeting which, given the COVID-19 context, will be held virtually on June 22-24, 2020.

Françoise Bono, PhD, Chief Scientific Officer of Onxeo, commented: "We continue to strengthen our understanding of AsiDNA™'s unique mechanism of action and have generated new data demonstrating its ability to specifically target drug-tolerant or persistent tumor cells that result in resistance to targeted therapies, and in particular, as we are demonstrating for the first time in this study, resistance to PARP inhibitors. We are delighted to be able to present at this prestigious oncology-focused meeting this new study on the effect of AsiDNA™ on these persistent cells when combined with PARP inhibitors. These results add to AsiDNA™'s strong preclinical file, reinforce the legitimacy of its current development in the clinical setting and confirm its interest and value in our Company's portfolio.”

These new data show for the first time that PARPi resistance can be caused by drug-tolerant cells, and that the addition of AsiDNA™ to PARP inhibitors prevents the regrowth of these cells, thereby completely and irreversibly abolishing the emergence of resistance in ovarian tumor cells.

The results from this study are extremely encouraging for the upcoming Phase 1b/2 REVocan study, combining AsiDNA™ with niraparib in the clinical setting in recurrent ovarian cancer, which is expected to start in the second half of 2020. These data clearly reinforce AsiDNA™'s interest in the fight against resistance, which is the main challenge in cancer treatment today.

Session: PO.ET03.04 - Mechanisms of sensitivity and resistance to DNA damage repair targeting
Date/ Time: June 22, 2020 - 9:00 AM - 6:00 PM (U.S. Eastern Daylight Time -EDT)
E-poster: 4078 / 8

Click on this link to read the abstract: Acquired resistance to PARP inhibitors evolves from drug-tolerant persister cells vulnerable to AsiDNA™.

About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

www.onxeo.com

rationeel 27 mei 2020 12:07

0

Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation

The press release in PDF

Paris (France), May 27, 2020 – 8:45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services.

Bryan Garnier & Co. will now follow Onxeo's share price on the Euronext Paris stock exchange* and values the Company at 1.22 euro per share*.

For more information: www.bryangarnier.com ou drayot@bryangarnier.com (Head of Corporate Sales).

* This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. Onxeo and Bryan Garnier & Co have agreed on a service for the production and distribution of financial analyses.

About Bryan Garnier & Co
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.

About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

www.onxeo.com

rationeel 27 mei 2020 14:55

0

0.687 EUR +40.06%

RW1963 27 mei 2020 17:19

0

Zeer mooie stijging vandaag.
Wat te doen?
Zal het verder stijgen of komt er weer een omslagpunt?
Ik sta nog lang niet Breakeven.

rationeel 27 mei 2020 18:54

1

Ik ook niet. Maar nu heb ik toch spijt niet op die laagste prijs te hebben bijgekocht.

Is de stijging omdat Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation,
of omgekeerd, omdat ze zo goed gaan, heeft Bryan Garnier & Co zin om te gaan volgen en koop aanbevelingen af te geven.

Hij had in ieder geval goedkoop kunnen inslaan;)

rationeel 27 mei 2020 19:25

0

Laatste ...*** 0,837***... 17:39:50 Theor. open 0,837 17:35:10
Bied 0,82 17:40:01 Laat 0,84 17:40:05
Laagste ...***0,512***... 09:00:23 Hoogste ...***0,862***... 15:57:00
Open 0,518 09:00:23 Vorig slot 0,4905 26-05-20
Cum. vol...***9.310.474***... Gem. dagomzet ...***269.348***...

Een plus van 70,64%

voorschoten 28 mei 2020 09:35

0

Ooit voor € 1,- gekocht.
En maar zakken, zakken.
Gaat het nog wat worden ?
Lachen hoor.

rationeel 28 mei 2020 13:00

0

quote:
voorschoten schreef op 28 mei 2020 09:35:
Ooit voor € 1,- gekocht.
En maar zakken, zakken.
Gaat het nog wat worden ?
Lachen hoor.

Ja, het kon nog veel lager.

Maar het zal het laatste aandeel in de biotechnologie niet zijn, dat ook nog weer veel hoger bleek te kunnen.

En dar hopen we dan maar op:)

Vertraagd	25 apr 2024 15:22
Koers	0,112
Verschil	-0,003 (-2,61%)
Hoog	0,115
Laag	0,110
Volume	34.522
Volume gemiddeld	99.352
Volume gisteren	27.666

Onxeo SA « Terug naar discussie overzicht

Onxeo 2020

Meedoen aan de discussie?

Direct naar Forum

Detail

VALERIO TX nieuws